Methylphenidate in Pediatric Brain Tumor Survivors With Cancer-related Fatigue

Cancer-related fatigue is a common and debilitating late effect in pediatric brain tumor survivors. Currently, evidence-based recommendations to ameliorate this condition are lacking. The researchers will investigate the ability of methylphenidate to improve fatigue and cognition in pediatric brain tumor survivors suffering from cancer-related fatigue. Methylphenidate is a drug (central nervous stimulant) most commonly used in the treatment of hyperkinetic disorders such as attention-deficit/hyperactivity disorder (ADHD). If methylphenidate shows an effect, the prospects are important for this patient group, since methylphenidate may then be included as part of the treatment of brain tumor-related fatigue.

NCT Number	NCT06905587
Lead Sponsor	Odense University Hospital Collaborators: Aarhus University Hospital Skejby, Aalborg University Hospital, Rigshospitalet, Denmark, University of Southern Denmark
Conditions	Brain Tumor, Pediatric, Cancer-related Fatigue, Methylphenidate
Enrollment	50 participants
Start Date	2025-09-02
Primary Completion	2029-12 (estimated)
Study Completion	2029-12 (estimated)
Updated on ClinicalTrials.gov	2026-06-26